FDA Drug Establishment Inspection: What Foreign Manufacturers Should Expect During a GMP Audit

An FDA inspection of a foreign drug manufacturing facility is one of the most consequential regulatory events a manufacturer can experience. The inspection determines whether the facility's manufacturing practices comply with US Current Good Manufacturing Practice (CGMP) requirements under 21 CFR Parts 210 and 211, and the outcome directly affects the facility's ability to export drug products to the United States. A favorable inspection outcome means continued market access. An unfavorable outcome — documented in Form FDA 483 observations and potentially followed by a Warning Letter — can result in import alerts, product detention, and loss of US customers. Understanding what the FDA inspects, how the inspection proceeds, and how to respond to findings is essential for every foreign drug manufacturer that supplies the US market.

Types of FDA drug inspections

FDA conducts several types of inspections of drug manufacturing facilities. Pre-Approval Inspections (PAIs) are conducted before the FDA approves an NDA, ANDA, or supplement — the purpose is to verify that the manufacturing facility and processes described in the application are accurate and that the facility can consistently produce the drug product as specified. Surveillance inspections are routine inspections conducted on a periodic basis to verify ongoing CGMP compliance at registered establishments. For-Cause inspections are triggered by specific concerns — such as adverse event reports, product complaints, or intelligence suggesting CGMP violations. Compliance Follow-Up inspections verify that a facility has implemented the corrective actions promised in response to previous 483 observations or Warning Letters.

What FDA investigators examine

FDA investigators (also called Consumer Safety Officers or CSOs) follow a systematic approach to drug facility inspections, typically covering these major areas: the quality system and quality control unit, including the authority and independence of the QC function; buildings and facilities, including cleanliness, environmental controls, and segregation of operations; equipment maintenance, calibration, and cleaning validation; production and process controls, including compliance with master batch records and in-process testing; laboratory controls, including analytical method validation, OOS investigation procedures, and reference standard management; materials management, including receiving, quarantine, sampling, testing, and release of raw materials; packaging and labeling operations, including label reconciliation and control of printed packaging materials; and complaint handling and adverse event reporting procedures.

Form FDA 483 and how to respond

At the conclusion of the inspection, if the investigator has observed conditions that may constitute violations of the FD&C Act or its implementing regulations, the investigator issues Form FDA 483 — Inspectional Observations. Each observation describes a specific condition that the investigator considers to be a deviation from CGMP requirements. The facility has the opportunity to discuss the observations with the investigator during a closing meeting and to provide initial responses. After the inspection, the facility should submit a comprehensive written response within 15 business days, addressing each observation with a root cause analysis, specific corrective actions taken or planned, a timeline for implementation, and evidence of correction where available.

The quality of the 483 response is critical. The FDA evaluates the response to determine the appropriate classification of the inspection: No Action Indicated (NAI) if no significant violations were found, Voluntary Action Indicated (VAI) if violations were found but the facility's response demonstrates adequate corrective action, or Official Action Indicated (OAI) if significant violations were found and the response is inadequate. An OAI classification typically leads to a Warning Letter and may result in import alert listing.

Remote Regulatory Assessments

Since the COVID-19 pandemic, the FDA has supplemented its physical inspection program with Remote Regulatory Assessments (RRAs) for foreign facilities. During an RRA, FDA investigators review documents, records, and other materials submitted electronically by the facility, and may conduct video tours or interviews with facility personnel. RRAs are not a substitute for physical inspections — the FDA has stated that it intends to resume full physical inspection capacity — but they provide the agency with a tool to assess foreign facility compliance when travel is restricted or when the volume of required inspections exceeds available inspector capacity.

How FDABridge helps prepare for FDA inspections

FDABridge ensures that your drug establishment registration is current and accurate — the administrative prerequisite that makes your facility eligible for FDA inspection and market access. While CGMP inspection readiness requires operational preparation at the facility level, FDABridge handles the registration, listing, and US Agent functions that support your facility's regulatory standing with the FDA. Visit fdabridge.com/drug to see our drug registration services or fdabridge.com/contact to discuss your needs.